XML 16 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Net sales        
Net sales $ 995.2 $ 1,078.8 $ 2,796.4 $ 3,257.1
Cost of sales        
Total cost of sales 711.1 807.4 2,037.9 2,460.4
Gross profit 284.1 271.4 758.5 796.7
Selling and administrative expense 226.0 219.9 629.7 674.3
Research, development and engineering expense 30.2 36.8 93.4 109.8
Asset Impairment Charges 4.1 0.0 4.1 0.0
(Gain) loss on sale of assets, net 0.0 (8.5) 13.0 6.6
Total operating expense 260.3 248.2 740.2 790.7
Operating profit (loss) 23.8 23.2 18.3 6.0
Other income (expense)        
Interest income 1.9 1.9 5.4 7.0
Interest expense (144.3) (52.5) (240.6) (153.3)
Foreign exchange gain, net (2.3) (1.8) (9.5) (4.1)
Miscellaneous, net (1.5) (1.0) 4.1 (2.8)
Loss before taxes (122.4) (30.2) (222.3) (147.2)
Income tax (benefit) expense (21.5) 5.2 (4.9) 74.8
Equity in earnings of unconsolidated subsidiaries 0.0 0.6 0.0 0.0
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total (100.9) (34.8) (217.4) (222.0)
Net (loss) income attributable to noncontrolling interests 0.5 0.9 0.5 (3.3)
Net loss attributable to Diebold Nixdorf, Incorporated $ (101.4) $ (35.7) $ (217.9) $ (218.7)
Weighted-average number of common shares used in basic and diluted loss per share (1) 77.7 76.8 77.5 76.6
Earnings Per Share [Abstract]        
Basic and diluted loss per share $ (1.31) $ (0.46) $ (2.81) $ (2.86)
Service [Member]        
Net sales        
Net sales $ 588.9 $ 643.0 $ 1,736.4 $ 1,931.0
Cost of sales        
Total cost of sales 399.2 462.4 1,226.5 1,423.3
Product [Member]        
Net sales        
Net sales 406.3 435.8 1,060.0 1,326.1
Cost of sales        
Total cost of sales 311.9 345.0 811.4 1,037.1
Retained Earnings [Member]        
Other income (expense)        
Net loss attributable to Diebold Nixdorf, Incorporated $ (101.4) $ (35.7) $ (217.9) $ (218.7)